Emerging therapeutic strategies to prevent infection-related microvascular endothelial activation and dysfunction

Ilyse Darwish¹ and W Conrad Liles¹,²,³,*

¹Sandra A. Rotman Laboratories; Sandra Rotman Centre for Global Health; University Health Network-Toronto General Hospital; Toronto, ON Canada; ²Division of Infectious Diseases; Department of Medicine; University of Toronto; Toronto, ON Canada; ³Department of Medicine; University of Washington; Seattle, WA USA

Keywords: endothelium, microvascular leak, emerging therapeutics, infectious diseases, sepsis, acute lung injury

Abbreviations: VEGFR2, vascular endothelial growth factor receptor 2; S1P, sphingosine-1-phosphate; ARF6, ADP ribosylation factor 6; ARNO, ARF nucleotide binding site opener; CAMs, cellular adhesion molecules; Ang-1/2, angiopeptin-1/2; ANP, atrial natriuretic peptide; NPR, natriuretic peptide receptor; PAK1, Rac-dependent p21-activated kinase; IFN-α, interferon-α

Recent evidence suggests that loss of endothelial barrier function and resulting microvascular leak play important mechanistic roles in the pathogenesis of infection-related end-organ dysfunction and failure. Several distinct therapeutic strategies, designed to prevent or limit infection-related microvascular endothelial activation and permeability, thereby mitigating end-organ injury/dysfunction, have recently been investigated in pre-clinical models. In this review, these potential therapeutic strategies, namely, VEGFR2/Src antagonists, sphingosine-1-phosphate agonists, fibrinopeptide Bβ₃, slit2N, secinH3, angiopeptin-1/tie-2 antagonists, angiopeptin-2 antagonists, statins, atrial natriuretic peptide, and mesenchymal stromal (stem) cells, are discussed in terms of their translational potential for the management of clinical infectious diseases.

Introduction

Microvascular leak caused by compromised vascular barrier function plays an important role in the pathogenesis and disease progression for a range of infectious syndromes, including sepsis,¹ acute lung injury,² dengue hemorrhagic fever and shock syndrome,³ viral hemorrhagic fevers,⁴ and hantavirus pulmonary syndrome.⁵ The main component of the vascular barrier is the endothelial cell monolayer, which is comprised of endothelial cells themselves and associated endothelial cell–cell junctions, including both adherens junctions and tight junctions, as well as a variety of extracellular components (e.g., the glycocalyx and the basement membrane).

Tight junctions, also referred to as zonula occludens, are predominantly composed of occludins and claudins, and are commonly located at the apical surface of the inter-endothelial cell cleft. Vascular surfaces that require tight regulation of endothelial cell permeability, such as the blood–brain barrier, are typically comprised of well-developed tight junctions. Adherens junctions are predominantly composed of vascular endothelial cadherin (VE-cadherin). VE-cadherin contains an extracellular domain that connects to adjacent endothelial cells and an intracellular domain that connects to the actin cytoskeleton via a family of catenins (α-, β-, γ-, and p120 catenins).⁶ VE-cadherin is regulated by the Rho family of GTPases, including Rho1, Rac1, and Cdc42. Specifically, Rho mediates endothelial cell permeability and junction disassembly, while Rac enhances vascular endothelial cell barrier integrity.⁷

The semipermeable endothelial barrier allows for transport of fluids and solutes from blood vessels into tissues. However, in pathological states, increased endothelial cell permeability results in excess transit of proteins and solutes between endothelial cells (paracellular leak), thereby causing edema. Such gaps in the vascular barrier are predominantly regulated by VE-cadherin,⁸ but may also be regulated by additional components of the adherens junctions, as well as modification of tight junctions and distortion of the endothelial cell structure due to cytoskeletal remodeling.

Recent evidence suggests that preventing microvascular leak may represent a viable therapeutic strategy to decrease infection-related end-organ injury/dysfunction in infectious diseases, thereby improving clinical outcome. A number of therapeutic strategies have emerged that are intended to strengthen vascular barrier integrity (Table 1 and Fig. 1). The focus of this review is to summarize these emerging therapeutic strategies and highlight their reported effects in pre-clinical models of infectious diseases.

VEGFR2/Src Antagonists

Vascular endothelial growth factor (VEGF) is a glycoprotein that is generated and released by endothelial cells, lung epithelial cells, platelets, and leukocytes. VEGF is a well-established regulator of vascular permeability and exerts its effects through binding endothelial cell-specific membrane tyrosine kinase receptors, VEGFR1–3.¹⁰ Upon activation by its cognate ligand, VEGF2...
VEGFR2 antibody decreased hantavirus-directed endothelial cell permeability in vitro via inhibition of VEGF-induced VE-cadherin internalization. Similarly, pazopanib and dasatinib, FDA-approved inhibitors of VEGFR2 and Src family kinases, respectively, decreased endothelial permeability induced by pathogenic hantavirus in vitro, via inhibition of VE-cadherin internalization. These results suggest the possibility that targeting the VEGF pathway may be a therapeutic strategy for multiple infectious diseases characterized by endothelial barrier disruption.

**Sphingosine-1-Phosphate (S1P) Agonists**

Sphingosine-1-phosphate (S1P) is a signaling sphingolipid that is released from platelets and binds to G-protein-coupled S1P receptors, S1P1–5 (formerly known as Edg 1–5). Plasma S1P contributes to the maintenance of microvascular integrity by signaling through SIP 1 on endothelial cells. S1P1 signals through increases vascular permeability by promoting dissociation of VE-cadherin from the adherens junction through a VEGFR2-Src-VE-cadherin signaling pathway. In sepsis, elevated plasma soluble VEGFR1 (sVEGFR1) levels have been reported to predict 28-d mortality and multi-organ dysfunction. It has been hypothesized that increased production of sVEGFR2 promotes binding and neutralization of VEGF, thereby strengthening the endothelial barrier. However, the precise function of VEGF in sepsis is controversial, with studies implicating contrasting roles for VEGF in the pathophysiology of sepsis. An ongoing clinical trial evaluating the effects of a neutralizing anti-VEGF antibody (bevacizumab) in patients with septic shock should provide further insight regarding the potential use of VEGF-targeted therapeutics in sepsis.

Targeting the VEGF pathway has also been of interest in the treatment of viral hemorrhagic fever syndromes, including hantavirus-induced hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Administration of inhibitory VEGFR2 antibody decreased hantavirus-directed endothelial cell permeability in vitro via inhibition of VEGF-induced VE-cadherin internalization. Similarly, pazopanib and dasatinib, FDA-approved inhibitors of VEGFR2 and Src family kinases, respectively, decreased endothelial permeability induced by pathogenic hantavirus in vitro, via inhibition of VE-cadherin internalization. These results suggest the possibility that targeting the VEGF pathway may be a therapeutic strategy for multiple infectious diseases characterized by endothelial barrier disruption.

**Table 1. Emerging microvascular barrier-enhancing agents**

| Agent                                  | Mechanism of action                                                                 |
|----------------------------------------|-------------------------------------------------------------------------------------|
| VEGFR2/Src antagonists                 | • Decrease activation of Src family kinases                                         |
|                                        | • Inhibit VEGF-induced VE-cadherin internalization                                   |
|                                        | • Regulate αβ3 integrins                                                           |
| Sphingosine-1-phosphate agonists        | • Bind endothelial receptor S1P to activate Rho and enhance cadherin expression     |
|                                        | • Activate αβ3 integrins through Rac to stabilize the endothelial cytoskeleton      |
|                                        | • Block thrombin-activated PAR-1 signaling                                          |
|                                        | • Block VEGF induced VE-cadherin internalization                                    |
|                                        | • Downregulate IFN-α thereby dampening innate immune responses                      |
| Fibrinopeptide Bb15–42                 | • Binds VE-cadherin to stabilize interendothelial junctions                          |
|                                        | • Increases binding of the Src kinase Fyn with p190RhoGAP in parallel with decreasing Fyn association with VE-cadherin |
| Slit2N                                 | • Binds to Robo4 to reduce p120-catenin phosphorylation and increases p120 catenin association with VE-cadherin at the cell surface |
|                                        | • Inhibits ARF6 and VEGF signaling                                                  |
|                                        | • Attenuates endothelial cytoskeletal elements via Rac1                            |
| SecinH3                                | • Inhibits guanine nucleotide exchange factors such as ARNO to increase cell surface VE-cadherin |
| Angiopoietin-1/ Tie2 agonists           | • Bind Tie2 to downregulate VCAM-1 and E-selectin                                   |
|                                        | • Decrease NFκB-dependent gene expression                                          |
|                                        | • Block VEGFR2 signaling thereby decreasing VE-cadherin internalization             |
| Angiopoietin-2 antagonists              | • Decrease Ang-2 antagonism of Ang-1-induced endothelial stabilization              |
|                                        | • Inhibit Ang-2 induced activation of endothelial cell adhesion molecules and proinflammatory cytokines |
| Statins                                | • Downregulate P-selection and ICAM-1                                              |
|                                        | • Decrease NFκB-dependent gene expression                                          |
| Atrial natriuretic peptide             | • Attenuates p38 MAPK, NFκB and Rho-dependent signaling                             |
|                                        | • Increases Rac-dependent p21-activated kinase (PAK1) phosphorylation, resulting in endothelial cell barrier enhancement |
| Mesenchymal stromal (stem) cells        | • Increase expression of genes involved in tightening gap junctions, calcium signaling, and focal adhesions |
|                                        | • Secrete endothelial stabilizing factors including Ang-1 and KGF                   |
|                                        | • Restore β-catenin, VE-cadherin, occludin-1 and claudin-1 by producing soluble paracrine factors |
|                                        | • Decrease activation of innate immunity                                           |
| Abbreviations: VEGFR2, vascular endothelial growth factor receptor 2; S1P, sphingosine-1-phosphate; PAR-1, protease activated receptor 1; ARF6, ADP ribosylation factor 6; ARNO, ARF nucleotide binding site opener; VCAM-1, vascular cell adhesion protein 1; Ang-1/2, angiopoietin-1/2; ICAM-1, intercellular adhesion molecule 1; KGF, keratinocyte growth factor. |
the Rho family GTPase Rac, which activates αvβ3 integrins, to increase cortical actin formation, thereby enhancing stability of the endothelial cytoskeleton. Decreased plasma S1P has been demonstrated in several pathological conditions associated with vascular barrier dysfunction and microvascular leak, including cerebral malaria in children.
Protease-activated receptor-1 (PAR-1) is an important mediator of S1P, signaling that contributes to both endothelial barrier stability and dysfunction. PAR-1 activation by the serine protease thrombin can lead to increased endothelial cell permeability, while conversely, PAR-1 activation by activated protein C (APC) can lead to endothelial cell barrier protection. This finding suggests that APC may serve as an effective endothelial stabilizing therapeutic agent. However, in a murine model of hyperoxic lung injury, prophylactic or therapeutic administration of recombinant murine APC was unable to ameliorate lung injury. More importantly, several clinical trials in patients with severe sepsis or septic shock failed to demonstrate a therapeutic benefit of recombinant human APC on 28-d mortality, including one study in which recombinant human APC administration was associated with a higher risk of bleeding. These studies precipitated the withdrawal of recombinant human APC (drotrecogin alfa) from the worldwide market. A modified APC variant with minimal anticoagulant activity but preserved cell signaling functionality (5A-APC) was capable of reducing mortality by approximately 40% after bacterial infection or LPS challenge in murine models of sepsis, suggesting further testing of anticoagulant APC variants may be of interest.

Administration of S1P or pharmacological analogs has been demonstrated to preserve or enhance vascular integrity in a number of infectious diseases in which microvascular leak plays an important pathologic role. In vitro, addition of S1P to Andes virus (hantavirus)-infected cells blocked VE-cadherin internalization in response to VEGF, thereby increasing endothelial integrity. S1P administration has also been shown to stabilize the microvascular endothelium in several pre-clinical animal models. In a murine model of ventilator-induced lung injury and a canine model of LPS-induced ventilator associated acute lung injury, S1P administration attenuated lung vascular leak as documented by decreased Evans blue dye extravasation in the lung, decreased protein level in bronchoalveolar lavage fluid and decreased lung tissue volume (i.e., decreased “wet-to-dry” lung weight). Furthermore, S1P antagonism has been reported to increase vascular leak in vivo under physiological conditions.

Recently, the pharmacologic agent FTY720, a potent S1P receptor agonist licensed as an experimental drug (Gilenya™) by the FDA, was evaluated in phase III clinical trials of multiple sclerosis. Phosphorylated FTY720 (FTY720-P) and its analog (R)-AAL ([R]-AFD) exert similar effects to S1P. In vitro, both agents induced β-catenin and localization of VE-cadherin to adherens junctions, as well as antagonized VEGF-induced endothelial cell permeability. Similar effects were confirmed in vivo in a murine model of VEGF-induced vascular leak. In a murine model of influenza, (R)-AAL administration one hour after influenza virus inoculation decreased pulmonary edema and inflammation. Notably, (R)-AAL therapy exerted a greater therapeutic benefit than oseltamivir, the most widely used antiviral drug for the specific treatment of influenza. Furthermore, administration of (R)-AAL in combination with oseltamivir provided additional benefit over (R)-AAL administration alone. A follow-up study by the same group demonstrated that the benefits of S1P agonist administration ([R]-AAL, CYM-5442, or RP-002) were due to its ability to downregulate excessive cytokine/chemokine production by the host, an immunopathological feature of severe influenza disease, in response to decreased IFN-α production, an upstream regulator of early cytokine production. In a murine model of cerebral malaria, FTY720 was also shown to improve clinical outcome when administered therapeutically, either alone or as an adjunctive therapy in combination with the anti-malarial drug artesunate. This effect was attributed to increased integrity of the blood-brain barrier and enhanced endothelial stability, demonstrated by decreased Evans blue extravasation in the brain, reduced plasma sICAM-1 (a marker of endothelial activation), and increased angiopoietin-1 (a marker of endothelial stability).

In contrast, Puneet et al. reported that blockade of sphingosine kinase 1 (sphk1) protected mice from experimental sepsis by enhancing bacterial clearance without altering systemic S1P levels required to maintain vascular barrier integrity. Intriguingly, because S1P receptor stimulation can lead to subsequent receptor downregulation, S1P agonists can potentially serve as functional S1P, antagonists in certain circumstances. Thus, it is likely that S1P-targeted agents can exert both deleterious and beneficial effects depending on the contextual pathophysiological state. Taken together, current pre-clinical evidence warrants further evaluation of Sphk1/S1P modifying therapeutic agents in the treatment of infectious disorders associated with excessive cytokine production and consequent microvascular leak, such as influenza and sepsis.

Fibrinopeptide Bβ\textsubscript{15–42}

The fibrin N-terminal peptide Bβ\textsubscript{15–42} is a 28 amino acid cleavage product of fibrin that binds VE-cadherin and stabilizes interendothelial junctions. Because of its endothelial barrier stabilizing properties, the therapeutic use of fibrinopeptide Bβ\textsubscript{15–42} (also known as FX06) has recently been investigated. In murine models of vascular leak, including pneumonitis and shock (intranasal LPS and intravenous LPS administration, respectively), FX06 administration attenuated capillary leak in the lungs. In addition, FX06 administration improved survival by approximately 40% in a murine model of dengue shock. These effects were mediated by FX06-induced dissociation of the Src kinase Fyn from VE-cadherin, in parallel with Fyn association with p190RhoGAP, a RhoA antagonist. In a murine model of polymicrobial sepsis (cecal ligation and puncture), treatment with FX06 attenuated leukocyte infiltration and reduced proinflammatory cytokines in the lung, liver, and blood. Decreased tissue inflammation was attributed to FX06-sustained vascular integrity, thereby suppressing vascular leakage and subsequent inflammatory cell trafficking into the lungs. In support of this hypothesis, FX06 pretreatment of macrophages and endothelial cells was unable to reduce TLR2- and TLR4-induced inflammation; however, microvascular permeability was not specifically investigated in this study. These data suggest that FX06 therapy may represent a novel and effective adjunctive therapy to increase vascular stability, thereby preventing end-organ inflammation, edema, and dysfunction in disorders associated with vascular activation/dysfunction and microvascular leak.
**Slit2N**

Binding of the ligand Slit to its cognate endothelial receptor Robo4 inhibits inflammation-induced endothelial permeability by strengthening adherens junctions and modulating cytoskeletal dynamics.\(^{35-36}\) Endothelial cell monolayer permeability induced by several mediators in vitro, including VEGF, LPS, TNF, and IL-1β, was counteracted by treatment with Slit2N, the active fragment of Slit.\(^{34,35}\) This effect correlated with increased cell surface expression of VE-cadherin. Specifically, Slit2N increased p120-catenin-VE-cadherin association by reducing p120-catenin phosphorylation.\(^{35}\) Slit2N-Robo4 signaling may also increase cell surface VE-cadherin via inhibition of ARF6 signaling.\(^{34,37}\) These findings were substantiated in several experimental models of infectious diseases characterized by microvascular activation/dysfunction, including sepsis, LPS-induced lung injury, and H5N1 avian influenza. In each of these pre-clinical models, administration of Slit2N enhanced microvascular integrity and improved survival without dampening inflammation (or altering viral load in H5N1 experimental avian influenza).\(^{35}\) These findings suggest that therapeutic targeting of Robo receptors represents a promising strategy to improve clinical outcome in infectious diseases associated with endothelial dysregulation and microvascular leak.

**SecinH3**

Recently, Zhu et al.\(^{37}\) described a novel cytokine-mediated pathway involved in endothelial barrier stability that functions independently of MYD88-induced NFκB signaling. In vitro, various NFκB pathway inhibitors failed to rescue IL-1β-induced endothelial permeability or endothelial cell surface VE-cadherin internalization. The results from a series of elegant experiments demonstrated a requirement for the adaptor protein MYD88 in IL-1β induced endothelial permeability, suggesting that MYD88 mediates a distinct NFκB-independent pathway involved in endothelial activation/dysfunction.\(^{37}\) The investigators implicated a pathway involving MYD88 activation of the ARF guanine nucleotide-exchange factor inhibitor (GEF) ARNO, based on the observations that ARNO-ARF6 signaling decreased cell surface VE-cadherin and increased vascular permeability. Furthermore, administration of SecinH3, a GEF inhibitor, restored endothelial barrier function in murine models of inflammatory arthritis and acute inflammation, without affecting global cytokine expression.\(^{37}\) SecinH3 administration has also been shown to decrease endothelial leak in a murine model of vascular eye disease.\(^{34}\) Therapeutic agents that target the ARNO-ARF6 pathway, such as Slit2N and SecinH3, are emerging as important potential therapies for conditions associated with vascular destabilization.

**Angiopoietin-1/Tie-2 Agonists**

Angiopoietin-1 (Ang-1) is a ligand for the endothelial-specific receptor tyrosine kinase Tie2,\(^{58}\) a potent mediator of angiogenesis that functions post-development to prevent vascular leakage and promote vascular quiescence via strengthening of endothelial cell junctions and downregulation of surface adhesion molecules, such as vascular cell adhesion molecule-1 (VCAM-1) and E-selectin.\(^{59-62}\) The Ang-1/Tie2 axis also transdominantly blocks VEGFR2-mediated microvascular permeability.\(^{63}\) A variety of Ang-1/Tie2 targeted strategies have been investigated in pre-clinical models to reduce complications of infectious diseases. Both cell- and viral vector-based Ang-1 gene therapeutic strategies, including Ang-1 specifically engineered to potently induce Tie2 phosphorylation,\(^{64}\) have been reported to reduce microvascular leak in murine models of acute lung injury and acute kidney injury.\(^{7,64-67}\)

A synthetic Tie2 agonist peptide known as vasculotide (VT) has been shown to protect against vascular leak and mortality, with subsequent improvement in end-organ function, when administered in either a prophylactic or therapeutic regimen in a murine model of polymicrobial sepsis.\(^{68}\) VT has also been shown to prevent lung vascular leak and improve survival by 30–40% in a murine model of LPS-induced lung injury (intraperitoneal LPS administration).\(^{69}\) Another study by Alfieri et al.\(^{70}\) evaluated the effects of an Ang-1 mimetic, MAT.Ang-1, in experimental LPS-induced sepsis in mice. Therapeutic administration of a single dose of MAT.Ang-1, 20 h after LPS administration, decreased vascular leak without altering vascular resistance. A growing number of Ang-1/Tie2 agonists represent promising agents for the prevention or amelioration of infection-induced endothelial activation/dysfunction and consequential microvascular leak.
Atrial natriuretic peptide (ANP) plays an important physiological role in the maintenance of arterial blood pressure and volume. These effects are mediated by binding to natriuretic peptide receptors (NPRs) A–C. NPRs are guanylyl cyclase-linked, regulated by cGMP synthesis, and are highly expressed in the vascular endothelium. Vascular endothelial-specific NPR-A knockout mice developed systemic hypertension and cardiac hypertrophy, yet maintained a direct vasodilatory response to ANP. Pre-treatment with ANP reduced paracellular endothelial gaps and stabilized VE-cadherin in TNF-activated endothelial cells. These observations suggest that ANP moderates arterial blood pressure and volume via its effects on vascular permeability. ANP modulates signaling pathways important for the production of proinflammatory cytokines and remodeling of the endothelial cell cytoskeleton. In vitro, endothelial cells pre-treated with ANP followed by LPS stimulation displayed significantly attenuated p38 MAPK, NFκB, and Rho-dependent signaling 6 h post-LPS stimulation. In a murine model of LPS-induced lung injury, ANP modulated vasculature stability via increased Rac-dependent p21-activated kinase (PAK1) phosphorylation, resulting in increased endothelial cell barrier integrity. PAK1 is a cytoskeletal Rac effector protein that initiates peripheral actin polymerization.

Increased levels of ANP have been observed in patients with septic shock, and in murine models of lung injury. Moreover, ANP−/− mice have been reported to develop more severe LPS-induced lung injury and vascular leak compared with wild-type mice, suggesting a potential mechanistic role for ANP in sepsis and acute lung injury. Experimental acute lung injury-associated pulmonary edema induced by multiple stimuli—including thrombin, VEGF, LPS, peptidoglycan, and lipoteichoic acid—is reduced by concomitant or prophylactic ANP administration.

Evaluation of therapeutic ANP administration in patients with lung injury is limited. In a cohort of 40 individuals with acute lung injury requiring mechanical ventilation with positive end-expiratory pressure (PEEP), ANP administration improved lung injury and oxygenation. In contrast, Bindels et al. observed no difference in pulmonary gas exchange in ten patients with acute respiratory distress syndrome who received ANP. Large, randomized controlled trials are warranted to evaluate the use of exogenous ANP as a potential therapeutic agent for the treatment of infection-induced lung injury.

Mesenchymal Stromal (Stem) Cells

Mesenchymal stromal (stem) cells (MSCs) represent a heterogeneous subset of non-hematopoietic pluripotent stromal cells with multi-lineage potential that can be isolated from various tissues (e.g., adult bone marrow). While initial interest in MSCs was focused on their potential in regenerative medicine, a growing interest in their potential in immunomodulatory therapy has evolved based on their capacity to modulate the host response in diseases and syndromes associated with inflammation. It has been recently recognized that MSCs secrete an array of growth factors, cytokines, and lipid mediators that modulate host inflammation, improve pulmonary alveolar fluid clearance, and strengthen endothelial integrity thereby improving organ function and decreasing mortality in pre-clinical models of infectious diseases including LPS-induced acute lung injury and sepsis following cecal ligation and puncture.

MSC-mediated effects on the vascular endothelium have been investigated in vitro and in vivo. VEGF-treated pulmonary endothelial cells exposed to MSC-conditioned media preserved adherens junctions (β-catenin and VE-cadherin) leading to increased endothelial barrier stability. This finding was confirmed in a rat model of mild hemorrhagic shock (removal of 2 ml/100 g of blood over 10 min followed by resuscitation 1 h post-shock), where MSC administration decreased pulmonary edema, in part, by increasing adherens junction and tight junction protein expression, including VE-cadherin, claudin-1, and occludin-1. A network analysis of experimental sepsis-induced MSC-mediated effects on common transcriptional responses in major target organs identified coordinated expression of transcriptional programs involved in preserving endothelial/vascular integrity, including upregulation of genes associated with gap junction tightening, calcium signaling, focal adhesion, and the Ang-1/Tie-2 pathway.

Ang-1 and keratinocyte growth factor (KGF) are thought to play important roles in the induction of MSC-mediated therapeutic effects. In vitro, MSC-mediated alveolar cell permeability was attributed to Ang-1 production. Moreover, in...
a murine model of LPS-induced lung injury, Ang-1 transfected MSCs were more effective at restoring lung/vascular integrity than non-transfected MSCs. KGF production by MSCs was implicated in the restoration of alveolar fluid clearance in LPS-treated ex vivo-perfused human lungs.102

Future Directions and Limitations
Emerging pre-clinical therapeutic strategies that target microvascular endothelial barrier activation/dysfunction represent promising approaches to prevent and/or limit end-organ dysfunction/injury in infectious diseases (summarized in Table 2). In addition to the strategies discussed in this review, α,β integrin regulators such as Fibulin5, NRPI, and Syndecan1 warrant pre-clinical evaluation for possible applications to limit infection-related microvascular leak.109-111

Given that a variety of viral infections may mediate endothelial dysregulation, therapeutic agents that target the host endothelium could potentially have relatively broad utility in the management of serious viral infections. It will also be important to assess new barrier-enhancing agents in combination with established therapeutic modalities (e.g., in combination with oseltamivir for the specific treatment of influenza). This complementary and robust treatment approach should allow for optimal therapeutic efficacy by targeting the infectious agent and the deleterious host responses in concert. For example, endothelial-stabilizing agents may be more effective when antimicrobial replication is diminished.

Given the failure of multiple therapeutic strategies showing promise in pre-clinical testing to yield positive results in clinical trials for the treatment of sepsis,13,14 one must remain cautious when considering the therapeutic potential of endothelial stabilizing agents. It is also important to recognize that murine models, such as experimental sepsis, may fail to replicate important pathophysiological features of human disease.113,114 Well-designed, controlled clinical trials will be necessary to determine whether endothelial stabilization strategies will be effective in reducing infection-related morbidity and mortality associated with endothelial activation/dysfunction and associated microvascular leak.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
Grant support provided to support this work by a Canada Research Chair in Infectious Diseases and Inflammation from the Canadian Institutes of Health Research (WCL).

References

1. Goldenberg NM, Steinberg BE, Slutska AS, Lee WL. Broken barriers: a new take on sepsis pathogenesis. Sci Transl Med 2011; 3:88ra25; PMID:21607528; http://dx.doi.org/10.1126/scitranslmed.3002011
2. Mei SH, McCarter SD, Deng Y, Parker CH, Liles WC, Stewart DJ. Prevention of LPS-induced acute lung injury in mice by mesenchymal stem cells over-expressing angiopoietin 1. F100X Med 2007; 4:e269; PMID:17803352; http://dx.doi.org/10.1371/journal.pmed.0040269
3. Dalrymple NA, Mackow ER. Endothelial cells elicit immune-enhancing responses to dengue virus infection. J Virol 2012; 86:6408-15; PMID:22496214; http://dx.doi.org/10.1128/JVI.02121-12
4. Peters CJ, Zaki SR. Role of the endothelium in severe bacterial infection in Malawian children. Crit Care 2011; 15:R11; PMID:21703785; http://dx.doi.org/10.1186/cc10044
5. Shrivastava-Ranjan P, Rollin PE, Spiropoulou CF. Andes virus disrupts the endothelial barrier by induction of vascular endothelial growth factor and downregulation of VE-cadherin. J Virol 2010; 84:11227-34; PMID:20817034; http://dx.doi.org/10.1128/JVI.01485-10
6. Yuan SY, Rigor RR. Regulation of endothelial barrier function. San Rafael, CA: Morgan and Claypool Life Sciences, 2010.
7. Wójciak-Stothard B, Potempa S, Eichholtz T, Ridley AJ. Rho and Rac but not Cdc42 regulate endothelial barrier function. J Cell Biol 2001; 152:91-103; PMID:11275000
8. Verweber D, Broeermann A, Schulte D. Control of endothelial barrier function by regulating vascular endothelial-cadherin. Curr Opin Hematol 2010; 17:230-6; PMID:20393283; http://dx.doi.org/10.1097/MOH.0b013e32838f64b
9. Vandenbroucke E, Mehta D, Minshall R, Malik AB. Regulation of endothelial junctional permeability. Ann N Y Acad Sci 2008; 1125:134-45; PMID:18375586; http://dx.doi.org/10.1196/annals.1420.016
10. Olson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling - in control of vascular function. Nat Rev Mol Cell Biol 2006; 7:359-71; PMID:16633358; http://dx.doi.org/10.1038/srn1911
11. Gavard J, Garkus JS. VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. Nat Cell Biol 2006; 8:1223-34; PMID:1760996; http://dx.doi.org/10.1038/ncll486
12. Gavard J, Patel Y, Garkus JS. Angiopoietin-1 prevents VEGF-induced endothelial permeability by sequestering Src through mDia. Dev Cell 2008; 14:25-36; PMID:18194650; http://dx.doi.org/10.1016/j.devcel.2007.10.019
13. Yang KY, Liu KT, Chen YC, Chen CS, Lee YC, Peng RP, et al. Plasma soluble vascular endothelial growth factor receptor-1 levels predict outcomes of pneumonia-related septic shock patients: a prospective observational study. Crit Care 2011; 15:R11; PMID:2212663; http://dx.doi.org/10.1186/cc9412
14. Maddhambo LA, Banda DL, Jeffes G, White SA, Balmer P, Nikhoma S, et al.; IPD Study Group. The role of angiogenic factors in predicting clinical outcome in severe bacterial infection in Malawian children. Crit Care 2010; 14:R91; PMID:20492647; http://dx.doi.org/10.1186/cc9025
15. Pickkers P, Spongr T, Eijk Ljv, Hoeven Hv, Smits P, Deuente Mv. Vascular endothelial growth factor is increased during the first 48 hours of human septic shock and correlates with vascular permeability. Shock 2005; 23:48-52; PMID:15537779; http://dx.doi.org/10.1097/01.shk.0000190827.36406.0e
16. van der Flier M, van Leeuwen HJ, van Kessel KP, Kimpen JL, Hoefman AL, Geelen SP. Plasma vascular endothelial growth factor in severe sepsis. Shock 2003; 20:35-38; PMID:12614219; http://dx.doi.org/10.1097/000150728.34906.0e
17. Shapiro NI, And Wc. Sepsis and the broken endothelium. Crit Care 2011; 15:135; PMID:21545713; http://dx.doi.org/10.1186/cc10044
18. Pilot Study of Bevacizumab (Avastin) in Patients With Septic Shock. Available at: http://clinicaltrials.gov/ct2/show/NCT01030101 Accessed March 10, 2013.
Table 2. Experimental results of selected pharmacological agents that have been investigated for their ability to enhance endothelial barrier integrity and reduce vascular leak

| Infectious disease/infectious agent/model of vascular leak | Agent | Results |
|----------------------------------------------------------|-------|---------|
| Sepsis: Bevacizumab (VEGF antagonist) | Ongoing clinical trial<sup>18</sup> |
| APC | Failed to demonstrate therapeutic benefit in several clinical trials<sup>32-36</sup> |
| 5A-APC (APC variant) | ~40% reduction in mortality in murine LPS-induced endotoxemia model of sepsis and S. aureus or E. coli infection model of sepsis<sup>57</sup> |
| Bβ<sub>15-42</sub> (FX06) | Attenuated capillary leak in the lungs in murine model of sepsis (i.V. LPS administration),<sup>51</sup> reduced leukocyte infiltration and proinflammatory cytokines in the lung, liver and blood in a murine CLP model of sepsis<sup>52</sup> |
| Slit2N | Enhanced microvasculature integrity and improved survival in a murine CLP sepsis model<sup>53</sup> |
| Angiopoietin-1 | Decreased vascular leak in murine model of LPS-induced sepsis<sup>54</sup> |
| Vasculotide | Protected against vascular leak, improved end-organ function and increased survival (~40%) in a murine CLP model of sepsis<sup>55</sup> |
| Mesenchymal stromal (stem) cells | Improved organ function and decreased mortality in murine CLP model of sepsis<sup>56,105</sup> |
| Acute lung injury | 1. SIP agonist | Decreased pulmonary edema and attenuated vascular barrier dysfunction in murine and beagle dog lung injury models induced by LPS and high tidal volume mechanical ventilation<sup>56</sup> |
| Bβ<sub>15-42</sub> (FX06) | Attenuated capillary leak in the lungs in a murine pneumonitis model (intranasal LPS-administration)<sup>51</sup> |
| Slit2N | Enhanced microvasculature integrity and improved survival in a murine LPS model of ALI<sup>57</sup> |
| Angiopoietin-1 | Decreased microvascular leak in murine models of ALI<sup>58,66,67</sup> |
| Vasculotide | Prevented lung vascular leak and improved survival by ~30–40% in a murine LPS-induced (i.P. administration) model of ALI<sup>59</sup> |
| Statins | Decreased ICAM-1 and no effect on survival in a murine model of bacterial pneumonia<sup>60</sup> |
| ANP | Improved endothelial cell barrier integrity in murine LPS-induced lung injury model<sup>60</sup> |
| Mesenchymal stromal (stem) cells | Improved pulmonary alveolar fluid clearance in ex vivo perfused lung<sup>60</sup> and strengthened endothelial integrity, resulting in improved organ function and decreased mortality in murine models of ALI<sup>60,99,101</sup> |
| Influenza | SIP agonist ([R]-AAL) | Decreased pulmonary edema and inflammation in murine model of influenza, effective as adjunctive therapy in combination with oseltamivir<sup>61</sup> |
| Slit2N | Enhanced microvasculature integrity and improved survival in murine model of avian influenza (HSN1)<sup>62</sup> |
| Dengue shock syndrome | Bβ<sub>15-42</sub> (FX06) | Improved survival by ~40% in a murine model of dengue shock syndrome<sup>63</sup> |
| Malaria | SIP agonist (FTY720) | Preserved blood brain barrier integrity and enhanced endothelial stability in murine malaria model, effective as adjunctive therapy in combination with artesunate<sup>64</sup> |
| Hantavirus | Pazopanib and dasatinib (VEGFR2 and Src family kinase inhibitors) | Increased endothelial integrity in vitro<sup>65,66</sup> |
| SIP | Increased endothelial integrity in vitro<sup>65</sup> |

Agents are categorized by infectious disease/infectious agent/model of vascular leak. Abbreviations: VEGF, vascular endothelial growth factor; APC, activated protein C; SIP, sphingosine-1-phosphate; LPS, lipopolysaccharide; I.V., intravenous; CLP, cecal ligation and puncture; ALI, acute lung injury; I.P., intraperitoneal; ICAM-1, intercellular adhesion molecule 1.
30. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 cross-activation. Blood 2005; 105:3178-84; PMID:16256725; http://dx.doi.org/10.1182/blood-2004-10-3093.

31. Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Sr. Antibiotic therapy in severe sepsis and septic shock: a clinical practice guideline. Crit Care Med 2007; 35(2):414-43. PubMed | Google Scholar

32. Martí-Carvajal AJ, Solà I, Gluud C, Lathyris D, Abraham E, Laterre PF, Garg R, Levy H, Talwar D, Sr. Antibiotic therapy in severe sepsis and septic shock: a clinical practice guideline. Crit Care Med 2007; 35(2):414-43. PubMed | Google Scholar

33. Finney CA, Hawkes KA, Kain DC, Dbahangi A, Musoke C, Goust-Gawedzki C, et al. Sip is associated with protection in human and experimental cerebral malaria. Mol Med 2011; 17:17-25; PMID:21546683; http://dx.doi.org/10.2110/molmed.2010.00214.

34. Eisenstaedt R, Biewald M. Endothelial barrier protection by activated protein C through PAR-1-dependent sphingosine 1-phosphate receptor-1 cross-activation. Blood 2005; 105:3178-84; PMID:16256725; http://dx.doi.org/10.1182/blood-2004-10-3093.

35. Suarez-Sobal I, Li JT, Wu N, Bhattacharya M, Zhu J, et al. Absence of integrin αvβ3 enhances vascular leak in mice by inhibiting endothelial cortical actin formation. Am J Respir Crit Care Med 2002; 165:1517-23; PMID:12096130; http://dx.doi.org/10.1164/rccm.200109-1519OC.

36. Finney CA, Hawkes KA, Kain DC, Dbahangi A, Musoke C, Goust-Gawedzki C, et al. Sip is associated with protection in human and experimental cerebral malaria. Mol Med 2011; 17:17-25; PMID:21546683; http://dx.doi.org/10.2110/molmed.2010.00214.

37. Garcia JGN, Liu F, Verin AD, Birukova A, Dechert R, et al. Sphingosine-1-phosphate receptor-1 crossactivation. J Biol Chem 2011; 286:1485-95; PMID:21195535; http://dx.doi.org/10.1074/jbc.M110.105691.

38. Pyne S, Pyne NJ. Translational aspects of sphingosine 1-phosphate biology. Trends Endocrinol Metab 2011; 17:463-72; PMID:21514226; http://dx.doi.org/10.1016/j.tem.2011.03.002.

39. Sanchez T, Estrada-Hernandez T, Paik HJ, Wu MT, Venkataraman K, Brinkmann V, et al. Phosphorylation and action of the immunomodulator FTY720 inhibit its vascular endothelial cell growth factor-induced vascular permeability. J Biol Chem 2003; 278:47281-90; PMID:12954648; http://dx.doi.org/10.1074/jbc.M306896200.

40. Walsh R, Teijaro JR, Rossen H, Oldstone MB. Quelling the storm: utilization of sphingosine-1-phosphate receptor signaling to ameliorate influenza virus-induced cytokine storm. Immunol Res 2011; 51:15-25; PMID:21901448; http://dx.doi.org/10.1007/s12026-011-8240-a.

41. Teijaro JR, Walsh KR, Calahan S, Fremden GM, Roberts E, Scott F, et al. Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 2011; 146:980-91; PMID:21925319; http://dx.doi.org/10.1016/j.cell.2011.08.015.

42. Puneet P, Yap CT, Wong L, Lam Y, Koh DR, Moocheadla S, et al. SphK1 regulates proinflammatory responses associated with endotoxin and polymeric viral sepsis. Science 2010; 328:1290-4; PMID:20522778; http://dx.doi.org/10.1126/science.1186355.

43. Jacobs-Caceres PJ, Hla T, Rosen H. Mapping pathways downstream of sphingosine-1-phosphate subtype 1 by differential chemical perturbation and proteomics. J Biol Chem 2007; 282:7254-64; PMID:17218309; http://dx.doi.org/10.1074/jbc.M610581200.

44. Bach TL, Barisic B, Chen H, Park KW, Sauvaget C, et al. Human recombinant protein C for severe sepsis in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369:836-43; PMID:17390452; http://dx.doi.org/10.1016/S0140-6736(07)61604-0.

45. Marti-Carvajal AJ, Sola I, Gluud C, Lathys H, Cardona AF. Human recombinant protein C for severe sepsis and septic shock in adult patients. Cochrane Database Syst Rev 2012; 12:CD004388; http://dx.doi.org/10.1002/14651858.CD004388.

46. Ranieri VM, Thompson BT, Barie PS, Dhainaut JE, Douglas IS, Finser F, et al.; PROWESS-Shock Study Group. Drotrecogin alfa (activated) in adults with severe sepsis and septic shock. N Engl J Med 2001; 344:699-709; PMID:11236773; http://dx.doi.org/10.1056/NEJMoa011112.

47. Kerschen EF, Fernandez JA, Cooley BC, Yang XV, Sud R, Mosnier LO, et al.; Endothoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. Curr Opin Crit Care 2009; 15:243-9; PMID:19783199; http://dx.doi.org/10.1097/jcc.0b013e3282b7e986.

48. McCarty BJ, Peng X, Hassoun PM, Sammami S, Simon BA, Garcia JG. Sphingosine-1-phosphate reduces vascular leak in murine and canine models of acute lung injury. Am J Respir Crit Care Med 2004; 170:987-94; PMID:14748902; http://dx.doi.org/10.1164/rccm.200405-684OC.

49. Sanna MG, Wang SK, Gonzalez-Cabrera PJ, Don A, Marsolais D, Matheu MP, et al. Enhancement of capillary leakage and restoration of lymphocyte egress by a chimeric angiopoietin-1 agonist in vivo. Nat Chem Biol 2006; 2:434-41; PMID:16829594; http://dx.doi.org/10.1038/nchembio804.
81. Darwish I, Mubareka S, Liles WC. Immunomodulatory
Bickel C, Rupprecht HJ, Blankenberg S, Espiniola-
Daly C, Pasnikowski E, Burova E, Wong V, Aldrich
Tzepi IM, Giamarellos-Bourboulis EJ, Carrer DP,
Parikh SM, Mammoto T, Schultz A, Yuan HT,
David S, Ghosh CC, Kümpers P, Shushakova N, Van
www.landesbioscience.com virulence 581
80. Omi H, Okayama N, Shimizu M, Fukutomi T,
Iwada K, Okouchi M, et al. Statins inhibit high
glucose-mediated neuporphyl-endothelial cell adhesion
during decreasing surface expression of endothelial
adhesion molecules by stimulating production of endo-
thelial nitric oxide. Microvasc Res 2003; 65:118-24;
PMID:12686169; http://dx.doi.org/10.1006/smrw.2002.00033-X
Takeuchi S, Kawashima S, Rikaraka Y, Ueyama T,
Inoue N, Hirata K, et al. Cetravatin suppresses lipid-
polyanion-induced IACM-1 expression through
inhibition of Rho GTPTase in BAEC. Biochem Biophys Res
Commun 2000; 269:97-102; PMID:10694948;
http://dx.doi.org/10.1006/bbrc.2000.2238
Dichl W, Dultur J, Frick M, Alber HE, Schwarzacher
SP, Are P, et al. HMGC-Ro reduce inhibitors
regulate inflammatory transcription factors in human
endothelial and vascular smooth muscle cells. Arterioscl Thromb Vasc Biol 2003; 23:58-
63; PMID:12542255; http://dx.doi.org/10.1161/01.
ATV.0000004564.48735.20
Boyrd AR, Himonas CA, Rodriguez PJ, Orihuela
CJ. Impact of oral simvastatin therapy on acute
lung injury in mice during pneumococcal pneumo-
bac. Microbiol 2012; 12;73; PMID:22587610;
http://dx.doi.org/10.1001/jcm.2012.2372
Sahane K, Kruse MN, Fabreiz L, Zetsche B, Mikko
D, Skynabin BV, et al. Vascular endothelium is criti-
cally involved in the hypertensive and hypovolemic
actions of atrial natriuretic peptide. J Clin Invest 2015;
115;1666-74; PMID:15931955; http://dx.doi.org/10.1172/
JCI82360
Birukova AA, Xing J, Fu P, Yakubov B, Dubrovskyi O,
Fornate J, et al. Atrial natriuretic peptide attenuates
LPS-induced vascular lung: role of PAK1. Am J Physiol Lung Cell Mol Physiol 2010; 299:L65-
63; PMID:20729189; http://dx.doi.org/10.1152/
ajplung.00202.2009
Xing J, Birukova AA. APN attenuates inflammatory
signaling and Rho pathway of lung endothelial perme-
ability induced by LPS and TNFalpha. Microvasc Res
2010; 79:56-62; PMID:19935145; http://dx.doi.org/10.1006/
bbrc.1999.1461
Boshol AL, Hall A. Rho GTPTase and their effector
proteins. Biochem J 2000; 348:241-55; PMID:10814641;
http://dx.doi.org/10.1042/0264-6022380241
Hana N, Inoh H, Shirakami G, Suga S, Komatsu
Y, Yoshimasa T, et al. Detection of C-type natri-
uretic peptide in human circulation and marked
increase of plasma CNP level in septic shock patients.
Crit Care 2012; 16:R182; PMID:23036162;
http://dx.doi.org/10.1186/cc110917
94. Xing J, Moldobaeva N, Birukova AA. Atrial natriuretic
peptide attenuates inflammatory signaling and Rho
pathway of lung endothelial permeability induced by
LPS and TNFalpha. Microvasc Res 2010; 79:56-62;
PMID:19935145; http://dx.doi.org/10.1006/bbrc.2000.2238
93. Klinger JR, Tsai SW, Green S, Grinnell KL, Machan
HC, et al. Atrial natriuretic peptide attenuates
endothelial cell growth factor-induced pulmonary edema in mice with
multiorgan dysfunction syndrome. J Appl Physiol 2013; 114:307-15;
http://dx.doi.org/10.1152/japplphysiol.00284.2010
92. Pedram A, Razandi M, Levin ER. Deciphering vascular
permeability factor signaling to vascular permeability
inhibition of thrombin-mediated changes in the morphology and permeability of endothelial
monocytes. Proc Natl Acad Sci U S A 2009; 106;13597-
13602; PMID:19935145; http://dx.doi.org/10.1073/
pnas.0907996106
91. Baron DA, Lofton CE, Newman WH, Currie MG.
Atriopeptin inhibition of thrombin-mediated
responses induced by mesenchymal stem cell treatment
in experimental sepsis induced by multiple
organ dysfunction and death in sepsis. Proc Natl
Acad Sci U S A 2013; 110:22321-6; PMID:24256035;
http://dx.doi.org/10.1073/pnas.1315270110
90. Hama N, Itoh H, Shirakami G, Suga S, Komatsu
Y, Yoshimasa T, et al. Detection of C-type natri-
uretic peptide in human circulation and marked
increase of plasma CNP level in septic shock patients.
Crit Care 2012; 16:R182; PMID:23036162;
http://dx.doi.org/10.1186/cc110917
99. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman
J, et al. Bone marrow-derived mesenchymal cells
in repair of the injured lung. Am J Respir Cell Mol Biol 2005; 33:145-52;
PMID:15891110; http://dx.doi.org/10.1165/rcmb.2004-0330OC
98. Rojas M, Xu J, Woods CR, Mora AL, Joodi R, Brigham KL,
Iyer S, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal
stem cells in mice. Am J Physiol Lung Cell Mol Physiol
2007; 293:131-41; PMID:1746739; http://dx.
doi.org/10.1152/ajplung.00202.2009
97. Bindels AJGH, van der Hoeven JG, Groeneveld PHP,
Hoffman EJ, Diktem DG, van der Poll T, et al. Atrial
natriuretic peptide improves survival in sepsis induced
by E. coli endotoxin-induced acute lung injury in the
ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009; 106:13585-62;
PMID:19721001; http://dx.doi.org/10.1073/pnas.0907996106
96. Bindels AJGH, van der Hoeven JG, Groeneveld PHP,
Hoffman EJ, Diktem DG, van der Poll T, et al. Atrial
natriuretic peptide improves survival in sepsis induced
by E. coli endotoxin-induced acute lung injury in the
ex vivo perfused human lung. Proc Natl Acad Sci U S A 2009; 106:13585-62;
PMID:19721001; http://dx.doi.org/10.1073/pnas.0907996106
95. Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaka K.
Beneficial effect of atrial natriuretic peptide on pulmonary
gas exchange in patients with acute lung injury.
Chest 1998; 114:223-8; PMID:9674473; http://dx.
doi.org/10.1378/chest.114.1.223
94. Xing J, Moldobaeva N, Birukova AA. Atrial natriuretic
peptide attenuates inflammatory signaling and Rho
pathway of lung endothelial permeability induced by
LPS and TNFalpha. Microvasc Res 2010; 79:56-62;
PMID:19935145; http://dx.doi.org/10.1006/bbrc.2000.2238
110. Beauvais DM, Ell BJ, McWhorter AR, Rapraeger AC. Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor. J Exp Med 2009; 206:691-705; PMID:19255147; http://dx.doi.org/10.1084/jem.20081278

111. Beauvais DM, Rapraeger AC. Syndecan-1 couples the insulin-like growth factor-1 receptor to inside-out integrin activation. J Cell Sci 2010; 123:3796-807; PMID:20971705; http://dx.doi.org/10.1242/jcs.067645

112. Wheeler DS. Another potential therapeutic agent for the management of critically ill patients with sepsis syndrome: same old story, same old result? Crit Care Med 2012; 40:1012-3; PMID:22343861; http://dx.doi.org/10.1097/CCM.0b013e3182f6d42

113. Dyson A, Singer M. Animal models of sepsis: why does preclinical efficacy fail to translate to the clinical setting? Crit Care Med 2009; 37(Suppl):S30-7; PMID:19104223; http://dx.doi.org/10.1097/CCM.0b013e318192bd3

114. Sook J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013; 110:3507-12; PMID:23401516; http://dx.doi.org/10.1073/pnas.1222878110